Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits2 as of December 31, 2025Revenues of €4.5…
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and…
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public…
Company Reaches Settlements in Two Separate Pending Litigation Cases to Resolve Large Portion of Potential Financial Liability February 06, 2026…
Press Release FY 2025 Preliminary and Unaudited Figures Highlighting Significant Progress in the Execution of the Genesis Plan Cash and…
January 13, 2026 07:05 ET | Source: Sight Sciences, Inc. MENLO PARK, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Sight…
January 13, 2026 07:05 ET | Source: Treace Medical Concepts, Inc. PONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) --…
January 11, 2026 09:30 ET | Source: RxSight, Inc. ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST)…
October 27, 2025 16:05 ET | Source: Pulmonx Corporation Glen French, member of the Board of Directors and former Pulmonx…
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…